Performance Summary

For more information on any of the categories below, please see our 2018/19 Combined Annual Report

Reporting Boundary

Our disclosure covers the businesses and operations over which we exercise direct control and incorporates CSL Limited, CSL Behring (including CSL Plasma), Seqirus, and global research and development (R&D), including Calimmune which was acquired in 2017. This includes our seven manufacturing facilities in Australia, Europe, the United Kingdom (UK) and the United States (US) as well as R&D, sales and marketing, distribution, and administration activities co-located with these facilities. Other R&D activities, sales and marketing, distribution, and administrative activities occurring away from our manufacturing facilities are also covered by this report, including the full network of donation centres, laboratories and administration offices operated by CSL Plasma.

Over the reporting period, we were working towards fully integrating systems and processes for the acquired operations in China – plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide). Unless otherwise indicated, data for Ruide has been excluded.

Our People

Key Performance Indicator

Measure

2016/17

2017/18

2018/19

Total headcount Number 19,637 22,220* 25,031*
Lost time injury frequency rate (LTIFR) Per million hours worked 1.56# 1.15# 2.24#
Medical treatment injury frequency rate (MTIFR) Per million hours worked 4.13# 3.41# 4.99#
Days lost frequency rate (DLFR) Per million hours worked 33.27# 15.68# 58.17#
Fatalities (including contractors) Number 0# 0# 0#
Employee engagement Percentage 73# 75# 74#

Innovation

Key Performance Indicator 

Measure

2016/17

2017/18

2018/19

R&D investment US$ million 645 702# 832#

Safety and Quality

Key Performance Indicator 

Measure

2016/17#

2017/18#

2018/19#

Regulatory audits Number 343 374 440
Quality audits of suppliers Number 609 489 580
Safety related recalls of finished product Number 4 5 3

Economic Contribution

Key Performance Indicator 

Measure

2016/17#

2017/18#

2018/19#

Economic value generated US$ million 6,934 7,925* 8,552*
Economic value generated US$ million 6,909 7,500* 8,409*

Community

Key Performance Indicator 

Measure

2016/17

2017/18

2018/19

Total contribution US$ million 40.0 39.5 56.0
2016/17 and 2017/18 includes some data from the acquired Novartis influenza vaccine.
In 2018/19, CSL contributed 21.7 million# in support of product access initiatives across the world.


Marketing and Promotion

Key Performance Indicator 

Measure

2016/17

2017/18#*

2018/19#*

Breaches Number There were no breaches of marketing and promotional
activities by the US Food and Drug
Administration, European Medicines Agency or
Medicines Australia.

Environment

Key Performance Indicator 

Measure

2016/17

2017/18

2018/19

Energy consumption Petajoules 3.11 3.27 3.39
Greenhouse gas emissions Metric Kilotonnes 295 308 319
Water consumption Gigalitres 3.35 3.61 3.87
Waste Metric Kilotonnes 32.67 49.15 61.40
Waste recycling rate % 51 43 42
To facilitate reporting of data earlier than prior years, the reporting period has been restated to March and April for
each reported period.
Please see Environmental section of website for more information.


* Includes Ruide
# Data for nominated period or identified KPI has been assured by Ernst and Young.
Please see corresponding annual report for assurance statement.